Comparison of independent and combined metabolic effects of chronic treatment with ( pGlu ‐Gln)‐ CCK ‐8 and long‐acting GLP ‐1 and GIP mimetics in high fat‐fed mice
- 26 February 2013
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 15 (7) , 650-659
Abstract
Aim: The incretin hormones, glucagon‐like peptide‐1 ( GLP ‐1) and glucose‐dependent insulinotropic polypeptide ( GIP ) and cholecystokinin ( CCK ) are gastrointestinal peptides with important physiological effects. However, rapid enzymatic degradation results in short‐lived biological actions. Methods: This study has examined metabolic actions of exendin‐4, GIP [ mPEG ] and a novel CCK ‐8 analogue, ( pGlu ‐Gln)‐ CCK ‐8 as enzymatically stable forms of GLP ‐1, GIP and CCK , respectively. Results: All peptides significantly (p < 0.01–p < 0.001) stimulated insulin secretion from BRIN BD11 cells, and acute in vivo experiments confirmed prominent antihyperglycaemic and insulinotropic responses to GLP ‐1 or GIP receptor activation in normal mice. Twice daily injection of ( pGlu ‐Gln)‐ CCK ‐8 alone and in combination with exendin‐4 or GIP [ mPEG ] in high fat‐fed mice significantly decreased accumulated food intake (p < 0.05–p < 0.01), body weight gain (p < 0.05–p < 0.01) and improved (p < 0.05) insulin sensitivity in high fat‐fed mice. However, there was no evidence for superior effects compared to ( pGlu ‐Gln)‐ CCK ‐8 alone. Combined treatment of ( pGlu ‐Gln)‐ CCK ‐8 and exendin‐4 resulted in significantly (p < 0.05) lowered circulating glucose levels and improved (p < 0.05) intraperitoneal glucose tolerance. These effects were superior to either treatment regime alone but not associated with altered insulin concentrations. A single injection of ( pGlu ‐Gln)‐ CCK ‐8, or combined with exendin‐4, significantly (p < 0.05) lowered blood glucose levels 24 h post injection in untreated high fat‐fed mice. Conclusion: This study highlights the potential of ( pGlu ‐Gln)‐ CCK ‐8 alone and in combination with incretin hormones for the treatment of type 2 diabetes.Keywords
This publication has 32 references indexed in Scilit:
- Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanismsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- CCK Stimulation of GLP-1 Neurons Involves α1-Adrenoceptor–Mediated Increase in Glutamatergic Synaptic InputsDiabetes, 2011
- The future of incretin‐based therapy: novel avenues—novel targetsDiabetes, Obesity and Metabolism, 2011
- Impaired Insulin Secretion and Enhanced Insulin Sensitivity in Cholecystokinin-Deficient MiceDiabetes, 2011
- Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weightPeptides, 2011
- PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvementBritish Journal of Pharmacology, 2007
- Comparison of the subchronic antidiabetic effects of DPP IV–resistant GIP and GLP‐1 analogues in obese diabetic (ob/ob) miceJournal of Peptide Science, 2007
- Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amideDiabetes/Metabolism Research and Reviews, 2007
- Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusionDiabetes, 1996
- Rapid development of tolerance to the behavioural actions of cholecystokininNature, 1983